TY - JOUR
T1 - A familial C3GN secondary to defective C3 regulation by complement receptor 1 and complement factor H
AU - Chauvet, Sophie
AU - Roumenina, Lubka T.
AU - Bruneau, Sarah
AU - Marinozzi, Maria Chiara
AU - Rybkine, Tania
AU - Schramm, Elizabeth C.
AU - Java, Anuja
AU - Atkinson, John P.
AU - Aldigier, Jean Claude
AU - Bridoux, Frank
AU - Touchard, Guy
AU - Fremeaux-Bacchi, Veronique
N1 - Publisher Copyright:
Copyright © 2016 by the American Society of Nephrology.
PY - 2016/6
Y1 - 2016/6
N2 - C3 glomerulopathy is a recently described form of CKD. C3GN is a subtype of C3 glomerulopathy characterized by predominant C3 deposits in the glomeruli and is commonly the result of acquired or genetic abnormalities in the alternative pathway (AP) of the complement system. We identified and characterized the first mutation of the C3 gene (p. I734T) in two related individuals diagnosed with C3GN. Immunofluorescence and electron microscopy studies showed C3 deposits in the subendothelial space, associated with unusual deposits located near the complement receptor 1 (CR1)-expressing podocytes. In vitro, this C3 mutation exhibited decreased binding toCR1, resultingin lessCR1-dependent cleavageofC3bby factor 1.Both patients had normal plasma C3 levels, and the mutant C3 interacted with factor B comparably to wild-type (WT) C3 to form a C3 convertase. Binding of mutant C3 to factor H was normal, but mutant C3 was less efficiently cleaved by factor I in the presence of factor H, leading to enhanced C3 fragment deposition on glomerular cells. In conclusion, our results reveal that a CR1 functional deficiency is a mechanism of intraglomerular AP dysregulation and could influence the localization of the glomerular C3 deposits.
AB - C3 glomerulopathy is a recently described form of CKD. C3GN is a subtype of C3 glomerulopathy characterized by predominant C3 deposits in the glomeruli and is commonly the result of acquired or genetic abnormalities in the alternative pathway (AP) of the complement system. We identified and characterized the first mutation of the C3 gene (p. I734T) in two related individuals diagnosed with C3GN. Immunofluorescence and electron microscopy studies showed C3 deposits in the subendothelial space, associated with unusual deposits located near the complement receptor 1 (CR1)-expressing podocytes. In vitro, this C3 mutation exhibited decreased binding toCR1, resultingin lessCR1-dependent cleavageofC3bby factor 1.Both patients had normal plasma C3 levels, and the mutant C3 interacted with factor B comparably to wild-type (WT) C3 to form a C3 convertase. Binding of mutant C3 to factor H was normal, but mutant C3 was less efficiently cleaved by factor I in the presence of factor H, leading to enhanced C3 fragment deposition on glomerular cells. In conclusion, our results reveal that a CR1 functional deficiency is a mechanism of intraglomerular AP dysregulation and could influence the localization of the glomerular C3 deposits.
UR - http://www.scopus.com/inward/record.url?scp=85017140592&partnerID=8YFLogxK
U2 - 10.1681/ASN.2015040348
DO - 10.1681/ASN.2015040348
M3 - Article
C2 - 26471127
AN - SCOPUS:85017140592
SN - 1046-6673
VL - 27
SP - 1665
EP - 1677
JO - Journal of the American Society of Nephrology
JF - Journal of the American Society of Nephrology
IS - 6
ER -